1
Williams Robert O, Zhang Feng, Koleng John J, Pasternak Gavril W, Kolesnikov Yuri A: Compositions for treating pain of the mucous membrane. Epicept, August 3, 2005: EP1559418-A1 (9 worldwide citation)

Compositions useful for long-lasting pain relief from mucosal damage, such as mucosal inflammation, abrasions, ulcerations, lesions, trauma and incisions, without significant systemic absorption. The compositions of the invention are particularly suitable for application to the mucous membrane of th ...


2

3
Williams Robert O, Zhang Feng, Koleng John J, Pasternak Gavril W, Kolesnikov Yuri A: Methods and compositions for treating pain of the mucous membrane. Epicept, April 2, 2003: EP1296650-A2 (1 worldwide citation)

Compositions useful for long-lasting pain relief from mucosal damage, such as mucosal inflamation, abrasions, ulcerations, lesions, trauma and incisions, without significant systemic absorption. The compositions of the invention are particularly suitable for application to the mucous membrane of the ...


4
Pasternak Gavril, Pan Ying Xian: (kor3) Gene. Sloan Kettering Inst Cancer, May 9, 2001: EP1097204-A2

The present invention encompasses novel splice variant forms of the muopioid receptor-1 (KOR-3) and the polynucleotide sequences encoding the KOR-3 splice variants. The invention further encompasses methods of screening for compositions regulating the KOR-3 splice variant activities and the developm ...


5
Pasternak Gavril W, Pan Ying Xian: Identification and characterization of multiple splice variants of the mu opioid receptor gene. Sloan Kettering Inst Cancer, October 6, 2004: EP1463516-A2

The present invention encompasses novel splice variant forms of the mu-opioid receptor-1 (MOR-1) and the polynucleotide sequences encoding the MOR-1 splice variants. The invention further encompasses methods of screening for compositions regulating the MOR-1 splice variant activities and the develop ...


6

7
Pasternak Gavril: Agonistes et antagonistes des opiaces, Opiate agonists and antagonists. Sloan Kettering Institute For Cancer Research, OGILVY RENAULT SENCRLSRL, August 22, 1989: CA1258674

ABSTRACT OF THE DISCLOSURE Dihydromorphinone compound of the general formula HDM=N-Rwherein HDM is Imagewhere * indicates binding carbon R1 is an optionally substituted alkyl, alkylene,cycloalkyl, or cycloalkylene R2 is OH or H R3 is OH or OCH3 and R is N=R4, N-R4, Image NN=R4 R4 is an optionally su ...


8

9
Kolesnikov Yuri, Pasternak Gavril W: Compositions topiques comprenant un analgesique opioide et un antagoniste du n-methyl-d-aspartate (nmda), Topical compositions comprising an opioid analgesic and an nmda antagonist. Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, SMART & BIGGAR, January 27, 2000: CA2336902

A topical opioid paradigm was developed to determine analgesic peripheral effects of morphine. Topical morphine as well as peptides such as [D-Ala2,MePhe4,Gly(ol)5]enkephalin (DAMGO) produced a potent, dose-dependent analgesia using the radiant heat tailflick assay. The topical drugs potentiated sys ...


10
Kolesnikov Yuri, Pasternak Gavril W: Topical compositions comprising an opioid analgesic and an nmda antagonist. Memorial Sloan Kettering Inst, May 30, 2001: EP1102589-A1

A topical opioid paradigm was developed to determine analgesic peripheral effects of morphine. Topical morphine as well as peptides such as [D-Ala2,MePhe4,Gly(ol)5]enkephalin (DAMGO) produced a potent, dose-dependent analgesia using the radiant heat tailflick assay. The topical drugs potentiated sys ...